CRISPR THERAPEUTICS AG (CRSP) Forecast, Price Target & Analyst Ratings
NASDAQ:CRSP • CH0334081137
56.5 USD
-0.83 (-1.45%)
At close: Mar 6, 2026
56.08 USD
-0.42 (-0.74%)
After Hours: 3/6/2026, 8:09:50 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CRISPR THERAPEUTICS AG (CRSP).
Forecast Snapshot
Consensus Price Target
$84.28
+ 49.17% Upside
Next Earnings Forecast
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$1.23
Revenue Estimate1.711M
ChartMill Buy Consensus
77.14%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$84.28
Upside
+ 49.17%
From current price of $56.50 to mean target of $84.28, Based on 35 analyst forecasts
Low
$33.33
Median
$79.56
High
$330.75
Price Target Revisions
1 Month
16.50%
3 Months
4.95%
Price Target Summary
35 analysts have analysed CRSP and the average price target is 84.28 USD. This implies a price increase of 49.17% is expected in the next year compared to the current price of 56.5.
The average price target has been revised upward by 4.95% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
77.14%
CRSP was analyzed by 35 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about CRSP.
In the previous month the buy percentage consensus was at a similar level.
CRSP was analyzed by 35 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-17 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-02-13 | TD Cowen | Maintains | Hold -> Hold |
| 2026-02-13 | Needham | Maintains | Buy -> Buy |
| 2026-02-13 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-01-30 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-12-23 | Citizens | Reiterate | Market Outperform -> Market Outperform |
| 2025-12-23 | Needham | Reiterate | Buy -> Buy |
| 2025-11-26 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-12 | Citigroup | Maintains | Buy -> Buy |
| 2025-11-11 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-11-11 | Baird | Maintains | Neutral -> Neutral |
| 2025-11-10 | Needham | Maintains | Buy -> Buy |
| 2025-10-17 | B of A Securities | Maintains | Buy -> Buy |
| 2025-10-10 | Needham | Reiterate | Buy -> Buy |
| 2025-09-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-18 | JP Morgan | Initiate | Overweight |
| 2025-08-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-06 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-05 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-07-22 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-08 | Needham | Reiterate | Buy -> Buy |
| 2025-06-27 | Clear Street | Downgrade | Buy -> Hold |
| 2025-06-27 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-06-27 | Piper Sandler | Reiterate | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$1.23
Revenue Estimate1.711M
Revenue Q2Q97.80%
EPS Q2Q22.13%
Number of Analysts22
Next Earnings Revisions
Revenue (1 Month)
-30.84%
Revenue (3 Months)
-87.42%
EPS (1 Month)
-9.66%
EPS (3 Months)
-9.24%
Next Earnings Summary
CRSP is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -1.23 USD and the consensus revenue estimate is 1.71M USD.
The next earnings revenue estimate has been revised downward by 87.42% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 371.206M 30,833.83% | 37.314M -89.95% | 3.51M -90.59% | 59.782M 1,603.19% | 106.86M 78.75% | 667.69M 524.83% | 2.571B 285.06% | 6.613B 157.22% | 1.265B -80.87% | 1.605B 26.88% | 2.129B 32.65% | |
| EBITDA YoY % growth | -202.701M 68.77% | -447.307M -120.67% | -548.839M -22.70% | -472.956M 13.83% | -449.386M 4.98% | -333.509M 25.79% | 258.36M 177.47% | 463.08M 79.24% | 913.92M 97.36% | 1.356B 48.37% | N/A | |
| EBIT YoY % growth | -222.538M 66.94% | -466.566M -109.66% | -568.318M -21.81% | -525.084M 7.61% | -495.7M 5.60% | -233.008M 52.99% | 453.24M 294.52% | 205.4M -54.68% | 522.84M 154.55% | 789.18M 50.94% | 1.253B 58.77% | |
| Operating Margin | -59.95% | -1,250.38% | -16,191.40% | -878.33% | -463.88% | -34.90% | 17.63% | 3.11% | 41.33% | 49.17% | 58.85% | |
| EPS YoY % growth | -1.96 76.58% | -4.37 -122.96% | -5.41 -23.80% | -4.07 24.72% | -3.33 18.24% | -2.01 39.57% | 0.10 104.85% | 2.54 2,500.42% | 5.82 129.22% | 8.36 43.68% | 12.93 54.68% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -1.23 22.13% | -1.22 5.44% | -1.05 9.99% | -1.03 25.07% |
| Revenue Q2Q % growth | 1.711M 97.80% | 3.589M 302.35% | 17.026M 1,815.19% | 21.877M 2,432.06% |
| EBITDA Q2Q % growth | -115.785M 19.42% | -109M 11.87% | -119.534M -1.09% | N/A |
| EBIT Q2Q % growth | -136.637M 7.94% | -136.567M -2.63% | -109.878M 16.80% | -123.807M 20.00% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
17.64%
EPS Next 5 Year
19.82%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
347.65%
Revenue Next 5 Year
288.80%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
13.56%
EBIT Next 5 Year
22.37%
CRISPR THERAPEUTICS AG / CRSP Forecast FAQ
Can you provide the average price target for CRISPR THERAPEUTICS AG stock?
35 analysts have analysed CRSP and the average price target is 84.28 USD. This implies a price increase of 49.17% is expected in the next year compared to the current price of 56.5.
What is the next earnings date for CRSP stock?
CRISPR THERAPEUTICS AG (CRSP) will report earnings on 2026-05-04.
What are the consensus estimates for CRSP stock next earnings?
The consensus EPS estimate for the next earnings of CRISPR THERAPEUTICS AG (CRSP) is -1.23 USD and the consensus revenue estimate is 1.71M USD.
Can you provide the consensus rating for CRISPR THERAPEUTICS AG stock?
The consensus rating for CRISPR THERAPEUTICS AG (CRSP) is 77.1429 / 100 . This indicates that analysts generally have a positive outlook on the stock.